Vaccine Studies in HIV-infected Subjects

$267,288ZIAFY2009AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Paper 38587079 Paper 35411076 Paper 34213402 Paper 34166231 Paper 33730454 Paper 33587510 Paper 33587505 Paper 33493795 Paper 32866318 Paper 31272988 Paper 31000477 Paper 30364428 Paper 27959728 Paper 26702094 Paper 25142607 Paper 23482645 Paper 20479938

Abstract

VRC 100 was designed to recruit and screen HIV-infected subjects for therapeutic HIV vaccines, as well as other vaccines to be developed for use in HIV-infected individuals. The results of this screening study were used to determine if the subject met eligibility requirements for participation a vaccine study. Educational materials on vaccines were reviewed with and provided to subjects before enrollment into a vaccine study. VRC 101 was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by VRC and administered in a prime-boost regimen.

View original record on NIH RePORTER →